Answers are grounded in this paper and cite their sources.
Observational analysis revealed treatment changes in patients with chronic inflammatory demyelinating polyradiculoneuropathy, indicating unmet needs for more effective therapies.
Approximately one-third of the patients switched to a new treatment within 2 years after starting treatment, which could be partly due to limited efficacy of therapies in LOT1. The decrease in treatment duration after LOT1 may suggest limited utility of subsequent therapies. Frequent treatment changes and increased healthcare encounters in this subgroup highlight significant unmet needs in CIDP.
No takes yet. Share an insight, caveat, or question.
Alonso‐Alonso et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: